CNDP1 and Diabetic Kidney Disease: From Genetic Susceptibility to Therapeutic Targeting
Genes · 24.03.2026 · 17 (4) · 367
DOI: 10.3390/genes17040367 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 24.03.2026. Verfasst von Bulent Tolga Delibasi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Long School of Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA. Hauptthemen laut MEDLINE: Dipeptidases, Diabetic Nephropathies, Genetic Predisposition to Disease. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Diabetic kidney disease (DKD) affects a substantial proportion of individuals with diabetes mellitus and represents the leading cause of end-stage renal disease worldwide. Familial aggregation studies consistently demonstrate that genetic factors contribute significantly to DKD susceptibility beyond metabolic and hemodynamic determinants. The carnosine dipeptidase 1 (CNDP1) gene on chromosome 18q22.3 has emerged as a compelling susceptibility locus, with a trinucleotide (CTG) repeat polymorphism in exon 2 that encodes the Mannheim variant, which has demonstrated protective associations in selected populations. Individuals homozygous for the shorter (CTG)5 allele exhibit reduced serum carnosinase-1 concentrations and activity, resulting in elevated tissue carnosine levels. Carnosine exerts multiple renoprotective effects, including antioxidant activity, inhibition of advanced glycation end-product formation, and attenuation of profibrotic signaling. Experimental models demonstrate that genetic or pharmacological reduction in carnosinase activity attenuates diabetic kidney injury. Early clinical studies of carnosine supplementation report improvements in albuminuria and oxidative stress markers, though available trials are limited in size, duration, and population scope. Therapeutic targeting of CNDP1 via carnosinase inhibition, therefore, represents a biologically grounded yet still emerging pharmacological strategy. This review synthesizes genetic, molecular, and translational evidence supporting CNDP1 as a model for genetics-informed therapeutic development in DKD, while highlighting important population-specific variation in allele frequencies that constrain universal clinical applicability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Long School of Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
- Department of Biology, Health, and the Environment, University of Texas, San Antonio, TX 78249, USA.
- Department of Medicine/Nephrology, University of Arizona College of Medicine, Tucson, AZ 85724, USA.
- Department of Medicine/Endocrinology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
ORCID-Profile: Bulent Tolga Delibasi, Halil Kutlu Erol, Tuncay Delibasi
Zitieren
APA
Delibasi, B. T., Sarisen, M. I., Belitsos, M. T., Erol, H. K., & Delibasi, T. (2026). CNDP1 and Diabetic Kidney Disease: From Genetic Susceptibility to Therapeutic Targeting. Genes, 17(4), 367. https://doi.org/10.3390/genes17040367
Vancouver
Delibasi BT, Sarisen MI, Belitsos MT, Erol HK, Delibasi T. CNDP1 and Diabetic Kidney Disease: From Genetic Susceptibility to Therapeutic Targeting. Genes. 2026;17(4):367. doi:10.3390/genes17040367
BibTeX
@article{Delibasi2026,
author = {Delibasi, Bulent Tolga and Sarisen, Michael Ismail and Belitsos, Matthew Thomas and Erol, Halil Kutlu and Delibasi, Tuncay},
title = {CNDP1 and Diabetic Kidney Disease: From Genetic Susceptibility to Therapeutic Targeting},
journal = {Genes},
year = {2026},
volume = {17},
number = {4},
pages = {367},
doi = {10.3390/genes17040367}
}
EUVIMED